17,261 trials
Neurobehavioral Disinhibition
Primary: Stage 1: Change From Baseline in the Composite of the Clinical Impression Severity Scores on the Neuropsychiatric Inventory Clinician Rating Scale (NPI-C) Subscale of…
Advanced Hepatocellular Carcinoma · BCLC Stage A Hepatocellular Carcinoma · BCLC Stage B Hepatocellular Carcinoma
Primary: Progression-free Survival (PFS) — 23.1 percentage of participants
Acute Pain · Chronic Pain · Healthy Volunteer
Primary: Verbal Pain Score at the End of 5 Minutes of Skin Heating — 3.3; 3.1; 3.4; 3.1 score on a scale
Schizophrenia
Primary: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score — -16.1; -18.5; -14.2 score on a scale — p=0.2925
NSCLC Non-small Cell Lung Cancer
Primary: Event-free Survival (EFS) Rate — 73.4 percentage of participants
Intrahepatic Cholangiocarcinoma
Primary: Number of Participants With Tumor Complete Response (CR) — 7 Participants
Central Nervous System Diseases · Pediatric Disorder · Body Indication
Primary: Area Under the Curve (AUCinf) — 392.3; 493.3 h.mg/L
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Methamphetamine Use Disorder
Primary: Number of People With Meth-positive Urine Tests at Weekly Visits — 20; 13; 23; 9 Participants
Psoriasis
Primary: CD8+ Trm1 Cells in Lesional Skin at Baseline and Week 52 — 9.60; 26.71; 1.60; 16.63 number of cells
Adenocarcinoma of the Prostate
Primary: Percent of Participants With Freedom of PSA (Prostate Specific Antigen) Progression — 84; 66 Percent of patients with no progession
Resistant Hypertension
Primary: Dose-response (DR) Relationship of XXB750 With Respect to Change From Baseline in Systolic Blood Pressure (SBP) 24 Hours — -5.77; -6.41; -6.63; -6.66 mmHg — p=0.5651
Breast Cancer
Primary: Reactance — 2.28; 2.45; 2.55 score on a scale
Spinal Neoplasms
Primary: Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session — 18 Participants
Duchenne Muscular Dystrophy
Primary: Number of Participants With Any Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03) — 7; 9; 6; 4 Participants